NCT00362505终止3 期
An Open-label, Phase III Clinical Trial to Evaluate the Safety and Antiviral Activity of Clevudine in Chronic Hepatitis B Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials
Bukwang Pharmaceutical48 个研究点 分布在 2 个国家开始时间: 2004年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 试验地点
- 48
- 主要终点
- Efficacy:change from baseline in HBV DNA; Safety: clinically measured adverse events, abnormality of laboratory tests and abnormality of vital signs, ECG.
研究概览
简要总结
The purpose of this study is to determine safety and efficacy of clevudine 10 mg qd for 24 weeks after completion of 24-week treatment with clevudine 30 mg qd with 12 weeks follow-up period
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is between 18 and 60, inclusive
- •Patients who have completed L-FMAU-301 or L-FMAU-302 clinical trial.
- •Patient is HBsAg positive at week 48 in L-FMAU-301 or L-FMAU-
- •Patient has bilirubin levels less than 2.0 mg/dL, prothrombin time of less than 1.7 (INR), a serum albumin level of at least 3.5 g/dL at week 48 in L-FMAU-301 or L-FMAU-
- •Women of childbearing potential must have a negative serum (β-HCG) pregnancy test at screening.
- •Patient is able to give written informed consent prior to study start and to comply with the study requirements.
排除标准
- •Patients with HBV DNA < 4,700 copies/mL, ALT normalization and consecutive e seroconversion at week 40 and 48 in L-FMAU-301
- •Patients with HBV DNA < 4,700 copies/mL and ALT normalization in L-FMAU-302
- •Patient is currently receiving antiviral, immunomodulatory or corticosteroid therapy.
- •Patients previously treated with α-interferon, lamivudine, lobucavir, adefovir or any other investigational nucleoside for HBV infection.
- •Patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy.
- •Patient is coinfected with HCV, HDV or HIV.
- •Patient with clinical evidence of liver mass or hepatocellular carcinoma and α-Fetoprotein > 50 ng/mL
- •Patient is pregnant or breast-feeding.
- •Patient is unwilling to use an "effective" method of contraception during the study and for up to 3 months after the use of study drug ceases. For males, condoms should be used. Females must be surgically sterile (via hysterectomy or bilateral tubal ligation) or post-menopausal or using at least medically acceptable barrier method of contraception (i.e. IUD, barrier methods with spermicide or abstinence)
- •Patient has a clinically relevant history of abuse of alcohol or drugs.
- •Patient has a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, biliary diseases excluding asymptomic GB stone, neurological, cardiovascular, oncologic or allergic disease. The patient with a benign tumor except for liver mass, excluded if judged by an investigator that the continuation of study would be interfered by the tumor.
- •Patient has creatinine clearance less than 60mL/min as estimated by the following formula:
- •(140-age in years) (body weight [kg])/(72)(serum creatinine [mg/dL]) [Note: multiply estimates by 0.85 for women]
- •13.Patient whom investigator consider is not suitable in this study
结局指标
主要结局
Efficacy:change from baseline in HBV DNA; Safety: clinically measured adverse events, abnormality of laboratory tests and abnormality of vital signs, ECG.
次要结局
- Efficacy:; Proportion of patients with HBV DNA below the assay Limit of Detection; Proportion of patients with HBeAg loss and/or seroconversion (HBeAg loss and HBeAb gain); Proportion of ALT normalization
研究者
研究点 (48)
Loading locations...
相似试验
终止
2 期
Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo GroupHepatitis BNCT00313261Bukwang Pharmaceutical
终止
3 期
Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBVHepatitis BNCT00313287Bukwang Pharmaceutical180
终止
4 期
A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis BChronic Hepatitis BNCT01264133Bukwang Pharmaceutical200
终止
2 期
Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201Hepatitis BNCT00362700Bukwang Pharmaceutical33
终止
3 期
Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBVHepatitis BNCT00313274Bukwang Pharmaceutical80